重组人血管内皮抑素联合顺铂局部治疗恶性胸腹腔积液的临床观察  

Clinical observation of endostar combined with cisplatin(DDP) in treatment of malignant thoracic and celiac serous effusion

作　　者：郑俊琼[1] 詹颖[1] 廖雪燕[1] 

机构地区：[1]福建医科大学附属龙岩市第一医院放疗科,福建龙岩364000

出　　处：《中国现代医生》2015年第18期19-21,共3页China Modern Doctor

摘　　要：目的观察合并恶性胸腹腔积液的肿瘤患者予以重组人血管内皮抑素(恩度)联合顺铂局部胸腹灌注的近期疗效和安全性。方法 46例经病理细胞学检查确诊合并恶性胸腹腔积液患者随机分成两组:实验组予顺铂60 mg d1.8 q3w联合重组人血管内皮抑素45 mg d1.4.8 q3w稀释灌注于胸腔,或顺铂60 mg d1.8 q3w联合重组人血管内皮抑素60 mg d1.4.8 q3w稀释灌注于腹腔;对照组予以单药顺铂60 mg d1.8 q3w稀释灌注于胸腹腔,同时予以静脉化疗,观察恶性胸腹腔积液情况、生活质量及不良反应。结果在实验组中胸腹水控制情况、生活质量提高与对照组比较,差异有统计学意义,两组比较不良反应差异无统计学意义。结论恶性胸腹腔积液予以重组人血管内皮抑素联合顺铂,配合静脉化疗,对恶性胸腹腔积液控制有较好近期疗效,无明显不良反应。Objective To observe the efficacy and safety of thoracic and celiac injection of endostar with DDP in treatment of malignant thoracic and celiac serous effusion. Methods A total of 46 cases of diagnosed cancer patients with malignant thoracic and celiac serous effusion were randomly divided into two groups：the experimental group was injected with endostar 45 mg d1.4.8 q3 w combined with DDP 60 mg d1.8 q3 w or endostar 60 mg d1.4.8 q3 w combined with DDP 60 mg d1.8 q3w;the control group was injected with DDP 60 mg d1.8 q3 w combined with venous chemotherapy. The effective rate,quality of life（QOL）,drug adverse reaction and clinical efficacy were evaluated after the injection. Results The difference of the effective rate and QOL improvement rate between the two groups was statistical significance. The difference of drug adverse reaction between the two groups had no statistical significance. Conclusion Thoracic and celiac injection of endostar with DDP in treatment of cancer with malignant thoracic and celiac serous effusion has better short-term efficacy without obvious adverse reactions.

关 键 词：重组人血管内皮抑素 顺铂 恶性胸腹腔积液 

分 类 号：R730.5[医药卫生—肿瘤]